Ventilator Associated Pneumonia Case Study

Ventilator-associated pneumonia (VAP) is defined as pneumonia that develops 48 hours or longer after patients has intubated and received mechanical ventilation. An infection may develop if microscopic organisms or germs invade the intubation of the patient’s lower respiratory tract and lung parenchyma (Koenig, S. M., 2006). According to the 2009 National Healthcare Safety Network (NHSN) report, the accountability for ventilator-associated pneumonia (VAP) preventions includes hospital’s CEO and senior management. They must assure that the hospital supports an infection prevention and control program to adequately prevent ventilator-associated pneumonia (VAP). They must also ensure that proper training and educational programs are in place to
The role of the infection control team is to decrease the incidence of preventing ventilator-associated pneumonia (VAP), which includes policy, surveillance data, risk assessment, and infection prevention interventions. The CEO must explain the active involvement of all health care professionals in preventing ventilator-associated pneumonia (VAP) as well as the past data and outcomes of cases of ventilator-associated pneumonia (VAP), furthermore ensuring that all patients will be under the care of all evidence-based recommendations. The CEO must rely on the hospital’s infection control officer and the hospital’s infection control team to prevent ventilator-associated pneumonia (VAP) by assuring that all patients on ventilators are cared for using all evidence-based recommendations, which must be proven nationally to decrease the exposure of occurring ventilator-associated pneumonia (VAP). The infection control team must confirm or deny the accuracy of the data from the Consumers Reports (Rebmann, T.,